ADLM 2025 brought together more than 16,500 professionals and over 800 exhibitors, making it one of the most impactful gatherings in clinical diagnostics this year. The energy on the floor was palpable, and we were proud to be part of it.
At the Aviva booth, we connected with more than 185 attendees, a majority of whom worked in clinical laboratories and health systems actively engaged in diagnostic innovation. Our conversations spanned assay development, antibody sourcing, and the ongoing need for validated, reproducible reagents that can scale from research to diagnostics.
If you stopped by our booth at ADLM, thank you! Your questions, insights, and conversations were a highlight of the show. We’re always looking for ways to improve how we serve the scientific community, and your feedback helps guide everything from product development to the content we create.
Welcoming Clint Trapp to the Aviva Team
Another highlight from ADLM: we were thrilled to have Clint Trapp, our new Director of Sales, join us at the show! Clint’s presence marks the beginning of an exciting new chapter for our team. With his experience in scientific sales and his focus on building meaningful customer relationships, Clint is already bringing fresh energy and insight that will help us better support our partners across research and diagnostics.
Our booth members included Aviva's President Kevin Harvey, Director of Sales Clint Trapp, Director of R&D Ryan Wallace, and Business Development Manager Joseph Boeh.
Policy in Motion: What the LDT Ruling Means for Clinical Labs
Since our attendance at ADLM 2024, in just one year the diagnostics landscape has undergone a major shift. What began in 2024 as a significant regulatory challenge for clinical laboratories has now been reversed by the courts, changing the outlook for labs, test developers, and ultimately, patients.
Last spring, the FDA finalized a rule that would have expanded its oversight over laboratory developed tests (LDTs), asserting authority that had traditionally belonged to CLIA under the Centers for Medicare & Medicaid Services (CMS). At the time, the move raised red flags across the diagnostics community. Labs warned of operational strain, rising costs, and the potential loss of critical local testing capabilities.
To address these concerns, ADLM’s Policy & External Affairs Core Committee (PEACC) met with policymakers to voice these matters and stress the potential impact: ADLM’s findings indicated that “60% of surveyed hospital labs said they would be unable to comply with the FDA’s “unmet need” exception criteria and nearly 70% of those would stop offering the affected LDTs.” Therefore, the FDA’s proposed LDT regulation risked duplicating existing oversight, placing significant operational and financial strain on laboratories, hindering innovation, and ultimately delaying patient access to essential diagnostic testing.
Fast forward to spring 2025 - a federal court ruled that the FDA’s approach was unlawful, reaffirming the long-standing interpretation that LDTs are clinical services, not medical devices. This ruling preserves the status quo, keeping CLIA as the central regulatory framework for labs.
For companies like Aviva, this decision is more than just a legal update, it’s a reaffirmation of stability for the laboratories we serve. Our customers, especially those integrating recombinant antibodies into their LDT workflows, can continue to innovate without the threat of duplicative regulation or resource-intensive approval pathways.
It also means we can keep investing in flexible, high-performance reagents that support rapid assay development and validation. From early-stage research to clinical assay refinement, our tools are designed to meet real-world lab needs without compromise. As the regulatory climate evolves, we remain committed to empowering diagnostic labs with reliable solutions backed by scientific rigor and responsive support.
In the year ahead, we’ll continue to monitor the policy landscape and advocate for clarity, consistency, and collaboration. Because when labs are free to focus on science, patients ultimately benefit.
We were glad to be part of this year’s ADLM meeting and the important conversations shaping the future of diagnostics. To learn more about the policy landscape and what we’re keeping an eye on, we encourage you to read the full post on the ADLM website.
Check out their post here to read more about:
- Safeguarding patient access by preventing Medicare cuts
- Lab test harmonization
- Advocating for children’s health programs
Looking Ahead: What’s Next for Aviva
ADLM was just the start. We’re continuing to build momentum with upcoming releases, deeper customer engagement, and new scientific content to support your work. Whether you're exploring recombinant antibodies, developing immunoassays, or navigating regulatory shifts, we're here to provide high-performance tools and expert support.
We’re also preparing for our next major conference appearances and will be sharing updates focused on assay development, protein expression, and antibody validation. Be sure to follow us for updates and stay connected as we roll out more ways to support your research and diagnostic goals.
Your Feedback Matters: Help Us Shape What’s Next
Have thoughts on what stood out or what you’d like to see more of from Aviva? Let us know. You can reach out directly to info@avivasysbio.com or fill out a quick feedback form here, and we’ll continue working to deliver the solutions you need.
